A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

NCT00817635 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: LCI699
DRUG: Eplerenone
DRUG: LCI699-matching Placebo
DRUG: Eplerenone-matching Placebo

Sponsor

Novartis

Collaborators

[object Object]
[object Object]